General Biologicals Corporation
Taipei, Taiwan· Est.
Taiwan’s fast‑growing CDMO delivering end‑to‑end biologics manufacturing for oncology and immunology.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $120M
AI Company Overview
Taiwan’s fast‑growing CDMO delivering end‑to‑end biologics manufacturing for oncology and immunology.
OncologyImmunologyInfectious Diseases
Technology Platform
A modular, high‑throughput bioprocessing platform integrating single‑use bioreactors, continuous chromatography, and real‑time analytics for rapid cell line development and scale‑up across multiple expression systems.
Opportunities
Rapid expansion of biologics and cell‑therapy manufacturing in the Asia‑Pacific region provides GBC with a growing client base and the chance to become a preferred regional CDMO.
Risk Factors
Intense competition from larger global CDMOs and potential regulatory delays could limit market share and increase operational costs.
Competitive Landscape
GBC competes with WuXi AppTec, Samsung Biologics, and Lonza; its differentiation lies in Taiwan’s cost‑effective infrastructure, fast turnaround times, and a strong focus on emerging modalities such as CAR‑T and mRNA vaccines.